Danimer Scientific, Inc.
DNMR
$1.13
-$0.165-12.74%
| Weiss Ratings | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.14 | |||
| Price History | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.60% | |||
| 30-Day Total Return | -33.53% | |||
| 60-Day Total Return | -76.84% | |||
| 90-Day Total Return | -92.86% | |||
| Year to Date Total Return | -48.64% | |||
| 1-Year Total Return | -98.34% | |||
| 2-Year Total Return | -98.78% | |||
| 3-Year Total Return | -99.28% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -98.24% | |||
| 52-Week Low % Change | 29.50% | |||
| Price | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $73.60 | |||
| 52-Week Low Price | $1.00 | |||
| 52-Week Low Price (Date) | Feb 10, 2025 | |||
| 52-Week High Price (Date) | Mar 07, 2024 | |||
| Valuation | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.91M | |||
| Enterprise Value | 394.76M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -41.01 | |||
| Earnings Per Share Growth | -27.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.10 | |||
| Price/Book (Q) | 0.02 | |||
| Enterprise Value/Revenue (TTM) | 10.55 | |||
| Price | $1.13 | |||
| Enterprise Value/EBITDA (TTM) | -6.91 | |||
| Enterprise Value/EBIT | -4.54 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.99M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 229 243 7075 | |||
| Address | 140 Industrial Boulevard Bainbridge, GA 39817 | |||
| Website | www.danimerscientific.com | |||
| Country | United States | |||
| Year Founded | 2004 | |||
| Profitability | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -232.11% | |||
| Profit Margin | -297.10% | |||
| Management Effectiveness | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -7.96% | |||
| Return on Equity | -- | |||
| Income Statement | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 37.43M | |||
| Total Revenue (TTM) | 37.43M | |||
| Revenue Per Share | $12.51 | |||
| Gross Profit (TTM) | -23.92M | |||
| EBITDA (TTM) | -57.16M | |||
| EBIT (TTM) | -86.87M | |||
| Net Income (TTM) | -111.20M | |||
| Net Income Avl. to Common (TTM) | -111.20M | |||
| Total Revenue Growth (Q YOY) | -21.17% | |||
| Earnings Growth (Q YOY) | 45.62% | |||
| EPS Diluted (TTM) | -41.01 | |||
| EPS Diluted Growth (Q YOY) | 53.65% | |||
| Balance Sheet | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 22.19M | |||
| Cash Per Share (Q) | $7.41 | |||
| Total Current Assets (Q) | 69.87M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 211.59M | |||
| Current Ratio (Q) | 3.275 | |||
| Book Value Per Share (Q) | $70.08 | |||
| Total Assets (Q) | 643.77M | |||
| Total Current Liabilities (Q) | 21.33M | |||
| Total Debt (Q) | 413.04M | |||
| Total Liabilities (Q) | 432.18M | |||
| Total Common Equity (Q) | 211.59M | |||
| Cash Flow | DNMR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -8.28M | |||
| Cash from Financing (TTM) | 15.12M | |||
| Net Change in Cash (TTM) | -55.55M | |||
| Levered Free Cash Flow (TTM) | -26.48M | |||
| Cash from Operations (TTM) | -62.39M | |||
